Florida Financial Advisors LLC Purchases Shares of 955 Axon Enterprise, Inc (NASDAQ:AXON)

Florida Financial Advisors LLC purchased a new position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 955 shares of the biotechnology company's stock, valued at approximately $504,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital World Investors raised its holdings in shares of Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock worth $1,079,145,000 after acquiring an additional 841,772 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after buying an additional 812,337 shares in the last quarter. Norges Bank bought a new stake in Axon Enterprise during the fourth quarter valued at about $482,081,000. GQG Partners LLC bought a new stake in Axon Enterprise during the fourth quarter valued at about $478,349,000. Finally, GAMMA Investing LLC boosted its position in Axon Enterprise by 58,725.5% during the first quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock valued at $402,210,000 after purchasing an additional 763,431 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Michael Garnreiter sold 5,913 shares of the business's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the completion of the transaction, the director owned 17,740 shares in the company, valued at $13,482,400. The trade was a 25.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CRO Cameron Brooks sold 3,000 shares of the company's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the sale, the executive owned 19,447 shares of the company's stock, valued at $14,405,559.72. The trade was a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,642 shares of company stock valued at $30,500,428 in the last quarter. Insiders own 5.70% of the company's stock.

Axon Enterprise Price Performance

AXON traded down $4.39 during trading on Tuesday, reaching $745.87. The stock had a trading volume of 373,385 shares, compared to its average volume of 587,068. Axon Enterprise, Inc has a 1-year low of $279.02 and a 1-year high of $830.21. The stock has a 50 day moving average of $758.11 and a two-hundred day moving average of $642.83. The firm has a market capitalization of $58.07 billion, a price-to-earnings ratio of 180.16, a price-to-earnings-growth ratio of 86.36 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same period in the prior year, the business posted $1.15 earnings per share. Axon Enterprise's revenue for the quarter was up 31.3% compared to the same quarter last year. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AXON. Bank of America raised their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research note on Wednesday, June 4th. Barclays lifted their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. Wolfe Research assumed coverage on Axon Enterprise in a research note on Monday, July 7th. They issued an "outperform" rating on the stock. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the company an "overweight" rating in a research note on Friday. Finally, The Goldman Sachs Group upped their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $716.36.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.